Innovation Kyoto 2021 Investment Limited Partnership" ("KYOTO-icap FundⅡ"), managed by Kyoto University Innovation Capital Co.,Ltd. ("Kyoto iCAP") (Headquarters: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi) as an unlimited partner, has received an investment from "TOKIWA-Bio Inc. (Headquarters: Tsukuba City, Ibaraki Prefecture; Representative Director: Mahito Nakanishi) from "Nagoya University and Tokai Area University Wide Area Venture No.1 Investment Limited Partnership" whose general partner is Nippon Venture Capital Co., Ltd. (Headquarters: Tokyo; Representative Director: Minoru Tagaya).

Overview of the investment
Tokiwa Bio has developed stealth RNA vector (SRV) technology, which can stably express multiple genes over a long period of time without being incorporated into chromosomes, and by utilizing this technology, we have succeeded in efficiently producing high-quality iPS cells.

Currently, Tokiwa Bio is actively promoting the practical application of SRV-based technology for induction into iPS cells and various cell reprogramming technologies, as well as business development in Japan and overseas through the October 2025 Series B financing in which Kyoto iCAP participated.

With the acquisition of the shares, Kyoto iCAP will further strengthen its collaboration with Tokiwa Bio to further promote social implementation of university-originated innovations through R&D and commercialization support.

The amount and other terms and conditions of the transaction related to this share transfer will not be disclosed due to contractual confidentiality obligations between the parties and the inclusion of sensitive business information.

Kyoto iCAP will maintain its policy of fair and appropriate disclosure to investors and other interested parties, while aiming to enhance corporate value and achieve long-term business growth.

Company Profile : TOKIWA-Bio Inc.
Establishment : December 22, 2014
Business : Research, development and sales of stealth RNA vectors
Head Office: 2-1-6 Sengen, Tsukuba City, Ibaraki Prefecture, Japan
Representative Director: Mahito Nakanishi
HP : https://tokiwa-bio.com/

About Kyoto University Innovation Capital , Co. Ltd. (Kyoto iCAP):
As a wholly owned subsidiary of Kyoto University, KYOTO-iCAP provides investment and other business support to companies that utilize research results generated by Kyoto University and other national universities. KYOTO-iCAP currently operates the Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO -iCAP Fund Ⅰ") (established in January 2016) with a total value of 16 billion yen and the KYOTO-iCAP Fund Ⅱ (established in January 2021) with a total value of 18.1 billion yen. The KYOTO-iCAP Fund Ⅰ has a maturity of up to 20 years, and the KYOTO-iCAP Fund Ⅱ has a maturity of up to 17 years, enabling long-term support for the practical application of research results from Kyoto University, which is strong in basic research. In addition, a portion of the KYOTO-iCAP Fund Ⅱ will be invested in ventures originating from national universities in Japan other than Kyoto University.

Contact information for inquiries
Kyoto University Innovation Capital, Co. Ltd.
36-1 Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317, Japan
Osami Kono, Senior Officer, Business Development Department
TEL: 075-753-7588 FAX: 075-753-7592
E-mail: info@kyoto-unicap.co.jp